Inotiv Acquires HistoTox Labs
April 13, 2021
Inotiv, Inc. has entered into an agreement to purchase substantially all assets of HistoTox Labs, a histopathology contract research organization, for $22.0 million in cash. The acquisition (subject to financing and customary closing conditions) expands Inotiv's pathology and histology capabilities, adds a Boulder, Colorado facility with digital pathology and immunohistochemistry capabilities, and is expected to retain all HistoTox employees.
- Buyers
- Inotiv, Inc.
- Targets
- HistoTox Labs, Inc.
- Industry
- Healthcare Services
- Location
- Colorado, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
StatLab Acquires Histoserve GmbH and Remaining Stake in Diapath France SAS
August 13, 2025
Medical Devices
StatLab Medical Products completed the acquisitions of Germany-based Histoserve GmbH and the remaining stake in Diapath France SAS, bringing both businesses into the Diapath/StatLab European organization. The transactions expand StatLab’s direct commercial presence across the four largest European pathology markets (France, Germany, Italy and the UK) and strengthen service, distribution and equipment capabilities for pathology laboratories in those markets.
-
Veranex Acquires HORUS Scientific
May 1, 2024
Healthcare Services
Veranex has acquired HORUS Scientific, a pathology and histology provider, to deepen its preclinical pathology and histology capabilities and expand its North American service footprint. The acquisition adds specialized GLP-capable histopathology services to Veranex’s integrated medtech service platform and complements its existing Paris pathology capabilities.
-
Inotiv Acquires Protypia to Expand Protein/Peptide Bioanalytical Capabilities
July 7, 2022
Healthcare Services
Inotiv, Inc. completed the acquisition of Nashville-based Protypia, Inc., a protein/peptide bioanalytical company, for approximately $11.0 million in a combination of cash, Inotiv common shares and promissory notes. The deal adds quantitative tissue-based large-molecule mass spectrometry capabilities to Inotiv's bioanalytical offerings to support immuno-oncology, cell and gene therapy, and other drug development programs.
-
Inotiv Acquires Integrated Laboratory Systems (ILS)
January 10, 2022
Healthcare Services
Inotiv, Inc. (NASDAQ: NOTV) completed the acquisition of Integrated Laboratory Systems, LLC (ILS), a contract research organization based in Morrisville, North Carolina, from Sier Capital. The transaction consideration totaled $56.0 million (approximately $38.0 million cash and 429,118 Inotiv shares valued at $18.0 million); ILS reported roughly $20.0 million of revenue in 2021 and will be integrated to expand Inotiv's genetic toxicology, in vivo/in vitro toxicology, pathology, genomics, and computational toxicology capabilities.
-
Labcorp Acquires Toxikon Corporation
November 18, 2021
Healthcare Services
Labcorp has acquired Toxikon Corporation, a Bedford, Massachusetts-based contract research organization that provides nonclinical in vivo and in vitro testing for pharmaceutical, biotech and medical device clients. The acquisition expands Labcorp Drug Development's nonclinical testing capabilities and creates a strategic Boston-area footprint; Toxikon reported approximately $40 million in annual revenue and the deal closed in December 2021.
-
Atlas Antibodies Acquires HistoCyte Laboratories Ltd
February 1, 2021
Medical Devices
Atlas Antibodies AB has signed an agreement to acquire UK-based HistoCyte Laboratories Ltd, a maker of cell-line control materials for immunohistochemical assays. The deal combines Atlas's proteome-wide antibody reagent portfolio with HistoCyte's novel control materials to expand diagnostic and research offerings; closing was expected in early March 2021.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.